Patents by Inventor Mila T. Du

Mila T. Du has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/TACE inhibitors
    Publication number: 20040229924
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: June 17, 2004
    Publication date: November 18, 2004
    Applicant: WYETH
    Inventors: Jeremy I. Levin, Aranapakam M. Venkatesan, James M. Chen, Arie Zask, Vincent P. Sandanayaka, Mila T. Du, Jannie L. Baker
  • Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors
    Patent number: 6812227
    Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: November 2, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy I. Levin, James M. Chen, Derek C. Cole, Mila T. Du, Leif M. Laakso
  • Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
    Patent number: 6753337
    Abstract: Compounds of the formula: useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.
    Type: Grant
    Filed: December 21, 2001
    Date of Patent: June 22, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy I. Levin, Aranapakam M. Venkatesan, James M. Chen, Arie Zask, Vincent P. Sandanayaka, Mila T. Du, Jannie L. Baker
  • Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors
    Patent number: 6716833
    Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: April 6, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy I. Levin, James M. Chen, Derek C. Cole, Mila T. Du, Leif M. Laakso
  • Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors
    Publication number: 20040033988
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: February 27, 2003
    Publication date: February 19, 2004
    Applicant: Wyeth
    Inventors: Jeremy I. Levin, James M. Chen, Derek C. Cole, Mila T. Du, Leif M. Laakso
  • Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors
    Publication number: 20030212049
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: February 27, 2003
    Publication date: November 13, 2003
    Applicant: Wyeth
    Inventors: Jeremy I. Levin, James Ming Chen, Derek C. Cole, Mila T. Du, Leif M. Laakso
  • Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors
    Publication number: 20030008849
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: December 27, 2000
    Publication date: January 9, 2003
    Inventors: Jeremy I. Levin, James M. Chen, Derek C. Cole, Mila T. Du, Leif M. Laakso
  • Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
    Publication number: 20020086890
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: December 21, 2001
    Publication date: July 4, 2002
    Applicant: American Cyanamid Company
    Inventors: Jeremy I. Levin, Aranapakam M. Venkatesan, James M. Chen, Arie Zask, Vincent P. Sandanayaka, Mila T. Du, Jannie L. Baker
  • Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
    Patent number: 6358980
    Abstract: Compounds of the formula: useful in the treatment of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: March 19, 2002
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, Aranapakam M. Venkatesan, James M. Chen, Arie Zask, Vincent P. Sandanayaka, Mila T. Du, Jannie L. Baker
  • Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors
    Patent number: 6225311
    Abstract: Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: May 1, 2001
    Assignee: American Cyanamid Company
    Inventors: Jeremy I. Levin, James M. Chen, Derek C. Cole, Mila T. Du, Leif M. Laakso
  • Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
    Patent number: 5929097
    Abstract: The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha.
    Type: Grant
    Filed: October 6, 1997
    Date of Patent: July 27, 1999
    Assignee: American Cyanamid Company
    Inventors: Jeremy Ian Levin, Mila T. Du, Aranapakam Mudumbai Venkatesan, Frances Christy Nelson, Arie Zask, Yansong Gu
  • Urethanes and ureas that induce cytokine production
    Patent number: 5658945
    Abstract: The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 19, 1997
    Assignee: American Cyanamid Company
    Inventors: Semiramis Ayral-Kaloustian, Steven R. Schow, Mila T. Du, James J. Gibbons, Jr.
  • Urethanes and ureas that induce cytokine production
    Patent number: 5633280
    Abstract: The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: May 27, 1997
    Assignee: American Cyanamid Company
    Inventors: Semiramis Ayral-Kaloustian, Steven R. Schow, Mila T. Du, James J. Gibbons, Jr.
  • Urethanes and ureas that enhance the growth of bone marrow progenitor cells
    Patent number: 5616612
    Abstract: The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: April 1, 1997
    Assignee: American Cyanamid Company
    Inventors: Semiramis Ayral-Kaloustian, Steven R. Schow, Mila T. Du, James J. Gibbons, Jr.
  • Urethanes and ureas that induce cytokine production
    Patent number: 5602275
    Abstract: The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: February 11, 1997
    Assignee: American Cyanamid Company
    Inventors: Semiramis Ayral-Kaloustian, Steven R. Schow, Mila T. Du, James J. Gibbons, Jr.
  • Urethanes and ureas that induce cytokine production
    Patent number: 5545662
    Abstract: The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: August 13, 1996
    Assignee: American Cyanamid Company
    Inventors: Semiramis Ayral-Kaloustian, Steven R. Schow, Mila T. Du, James J. Gibbons, Jr
  • Urethanes and ureas that induce cytokine production
    Patent number: 5312831
    Abstract: The invention relates to novel ureas and urethanes of Formula I: ##STR1## which stimulate cytokine production and may be used to accelerate recovery from neutropenia accompanying radio- or chemotherapy, bone marrow transplantation, or infections. Compounds in the invention or pharmaceutical compositions employing these compounds may be useful in the treatment of cancer, AIDS, aplastic anemia, myelodysplastic syndrome, and infectious diseases, and in the enhancement of immune response.
    Type: Grant
    Filed: May 12, 1993
    Date of Patent: May 17, 1994
    Assignee: American Cyanamid Company
    Inventors: Semiramis Ayral-Kaloustian, Steven R. Schow, Mila T. Du, James J. Gibbons, Jr.
  • Antiatherosclerotic 1-piperazine-thicarboxamides
    Patent number: 4450272
    Abstract: This disclosure describes 4-heteroaryl-1-piperazinethiocarboxamides useful in the treatment of atherosclerosis in mammals.
    Type: Grant
    Filed: May 6, 1982
    Date of Patent: May 22, 1984
    Assignee: American Cyanamid Company
    Inventors: Mila T. Du, Robert G. Shepherd
  • Antiatherosclerotic 1-piperazinecarbonyl compounds
    Patent number: 4439606
    Abstract: This disclosure describes 4-aryl, -heteroaryl and -heteroarylmethyl-1-piperazinecarbonyl compounds which are capable of ameliorating atherosclerosis in mammals.
    Type: Grant
    Filed: May 6, 1982
    Date of Patent: March 27, 1984
    Assignee: American Cyanamid Company
    Inventors: Mila T. Du, Robert G. Shepherd